RU2018129874A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018129874A3 RU2018129874A3 RU2018129874A RU2018129874A RU2018129874A3 RU 2018129874 A3 RU2018129874 A3 RU 2018129874A3 RU 2018129874 A RU2018129874 A RU 2018129874A RU 2018129874 A RU2018129874 A RU 2018129874A RU 2018129874 A3 RU2018129874 A3 RU 2018129874A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662281842P | 2016-01-22 | 2016-01-22 | |
| US62/281,842 | 2016-01-22 | ||
| PCT/US2017/014007 WO2017127468A1 (en) | 2016-01-22 | 2017-01-19 | Anti-coagulation factor xi antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2021129189A Division RU2021129189A (ru) | 2016-01-22 | 2017-01-19 | Антитела против фактора свертывания xi |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018129874A RU2018129874A (ru) | 2020-02-25 |
| RU2018129874A3 true RU2018129874A3 (ru) | 2020-06-15 |
| RU2757314C2 RU2757314C2 (ru) | 2021-10-13 |
Family
ID=57963475
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018129874A RU2757314C2 (ru) | 2016-01-22 | 2017-01-19 | Антитела против фактора свертывания xi |
| RU2021129189A RU2021129189A (ru) | 2016-01-22 | 2017-01-19 | Антитела против фактора свертывания xi |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2021129189A RU2021129189A (ru) | 2016-01-22 | 2017-01-19 | Антитела против фактора свертывания xi |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10053515B2 (ru) |
| EP (1) | EP3405498A1 (ru) |
| JP (2) | JP7252760B2 (ru) |
| KR (1) | KR20180104036A (ru) |
| CN (2) | CN108884169B (ru) |
| AR (1) | AR107505A1 (ru) |
| AU (1) | AU2017209083A1 (ru) |
| BR (1) | BR112018014810A2 (ru) |
| CA (1) | CA3010224A1 (ru) |
| JO (1) | JOP20170013B1 (ru) |
| MA (1) | MA43660A (ru) |
| MX (2) | MX378572B (ru) |
| RU (2) | RU2757314C2 (ru) |
| TW (1) | TWI736575B (ru) |
| WO (1) | WO2017127468A1 (ru) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| NZ786442A (en) | 2016-06-14 | 2025-06-27 | Adimab Llc | Anti-coagulation factor xi antibodies |
| RU2758160C2 (ru) * | 2016-09-20 | 2021-10-26 | Байер Фарма Акциенгезельшафт | Новые антитела против фактора xi и их применения |
| IL308980A (en) | 2016-12-23 | 2024-01-01 | Novartis Ag | Antibodies against factor XI and methods of their use |
| WO2020029179A1 (en) * | 2018-08-09 | 2020-02-13 | Shanghai Benemae Pharmaceutical Corporation | Anti-factor xi antibodies |
| WO2019067425A1 (en) | 2017-09-26 | 2019-04-04 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR TREATING CARDIAC DISEASE BY REDIRECTED T-CELL IMMUNOTHERAPIES |
| US12371507B2 (en) | 2018-11-09 | 2025-07-29 | Beth Israel Deaconess Medical Center | CDCP1 antibodies and antibody drug conjugates |
| AU2020211905A1 (en) * | 2019-01-21 | 2021-08-05 | Aronora Inc. | Novel humanized antibodies against factor XI having anti-thrombotic and anti-inflammatory effects and uses thereof |
| WO2020163646A1 (en) * | 2019-02-08 | 2020-08-13 | Igm Biosciences, Inc. | Anti-gitr antigen-binding domains and uses thereof |
| WO2020211674A1 (zh) * | 2019-04-16 | 2020-10-22 | 四川科伦博泰生物医药股份有限公司 | 抗FXI/FXIa抗体及其用途 |
| CN110423278B (zh) | 2019-08-08 | 2020-07-17 | 上海博槿生物科技有限公司 | 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用 |
| JP7621344B2 (ja) | 2019-09-23 | 2025-01-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 線維芽細胞活性化タンパク質（ｆａｐ）を標的とすることによる腫瘍組織の破壊の方法 |
| EP4041290A4 (en) | 2019-09-23 | 2024-02-07 | The Trustees of the University of Pennsylvania | MONOCLONAL ANTIBODY AGAINST CANINE FIBROBLAST ACTIVATING PROTEIN WHICH CROSS-REACTS WITH MURINE AND HUMAN FIBROBLAST ACTIVATING PROTEIN (FAP) |
| JP2023531278A (ja) * | 2020-07-03 | 2023-07-21 | スチョー アルファマブ カンパニー リミテッド | 凝固第ｘｉ因子（ｆｘｉ）結合タンパク質 |
| JP2024539157A (ja) * | 2021-10-22 | 2024-10-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 第ｘｉ因子ａ２ドメイン結合抗体及びそれらの使用方法 |
| US20250034277A1 (en) * | 2021-11-30 | 2025-01-30 | Suzhou Alphamab Co., Ltd. | Method for preventing and/or treating thromboembolic diseases |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| EP0420937B1 (en) | 1988-06-21 | 1994-11-09 | Genentech, Inc. | Therapeutic compositions for the treatment of myocardial infarction |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| JPH0656382A (ja) | 1992-08-04 | 1994-03-01 | Kawasaki Steel Corp | コークス乾式消火装置のバケット巻上機の吊ビーム装置 |
| MA24512A1 (fr) * | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
| GB9818110D0 (en) | 1998-08-19 | 1998-10-14 | Weston Medical Ltd | Needleless injectors and other devices |
| US6096002A (en) | 1998-11-18 | 2000-08-01 | Bioject, Inc. | NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method |
| DE69942671D1 (de) | 1998-12-01 | 2010-09-23 | Facet Biotech Corp | Humanisierte antikoerper gegen gamma-interferon |
| NZ521182A (en) | 2000-03-03 | 2004-11-26 | Cambridge Antibody Tech | Human antibodies against eotaxin comprising VH adn VL domains and their use |
| PT1648509E (pt) | 2003-07-15 | 2012-10-18 | Amgen Inc | Anticorpos neutralizantes anti-ngf humanos como inibidores selectivos da via de ngf |
| US7208601B2 (en) * | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| CN101128483B (zh) * | 2004-12-21 | 2015-06-03 | 阿斯利康公司 | 血管生成素-2的抗体及其应用 |
| CN101120087A (zh) | 2004-12-21 | 2008-02-06 | 森托科尔公司 | 抗-il-12抗体、表位、组合物、方法和用途 |
| US8318906B2 (en) | 2005-04-15 | 2012-11-27 | The Regents Of The University Of California | EMP2 antibodies and their therapeutic uses |
| CN117534755A (zh) | 2005-05-09 | 2024-02-09 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| NZ564592A (en) | 2005-07-01 | 2011-11-25 | Medarex Inc | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
| SI1957539T1 (sl) | 2005-12-08 | 2013-05-31 | Medarex, Inc. | Humana monoklonska protitelesa proti protein tirozin kinazi 7 (PTK7) in njihova uporaba |
| EP1960434B1 (en) | 2005-12-08 | 2012-07-11 | Medarex, Inc. | Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 |
| JP5586952B2 (ja) | 2006-06-06 | 2014-09-10 | クルセル ホランド ベー ヴェー | 腸球菌に対する殺活性を有するヒトの結合分子及びその使用方法 |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| WO2009008916A2 (en) | 2007-03-22 | 2009-01-15 | The Regents Of The University Of Californina | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| GB0708585D0 (en) | 2007-05-03 | 2007-06-13 | Queen Mary & Westfield College | Novel antibody and use in diagnosis and therapy of arthropathies |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| EP3124497B1 (en) | 2007-09-14 | 2020-04-15 | Adimab, LLC | Rationally designed, synthetic antibody libraries and uses therefor |
| AU2008303796B2 (en) | 2007-09-26 | 2014-09-18 | Amgen Inc. | Heparin-binding epidermal growth factor-like growth factor antigen binding proteins |
| EP3002298B1 (en) | 2007-11-21 | 2019-08-28 | Oregon Health & Science University | Anti-factor xi monoclonal antibodies and methods of use thereof |
| US8188235B2 (en) | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
| WO2009154461A1 (en) | 2008-06-19 | 2009-12-23 | Prothix Bv | Use of anti-factors xi antibodies for prevention of thrombus formation |
| US9000131B2 (en) | 2008-07-31 | 2015-04-07 | The Regents Of The University Of California | Antibodies that neutralize botulinum neurotoxins |
| SMT201700127T1 (it) | 2008-10-31 | 2017-03-08 | Janssen Biotech Inc | Antagonisti del recettore 3 di tipo toll |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| ES2720594T3 (es) * | 2008-12-18 | 2019-07-23 | Univ Oregon Health & Science | Anticuerpos anti-fXI y métodos de uso |
| AU2010226391C1 (en) | 2009-03-20 | 2016-11-24 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| AU2010236256C1 (en) | 2009-04-16 | 2015-10-22 | Abbvie Biotherapeutics Inc. | Anti-TNF-alpha antibodies and their uses |
| JP5694923B2 (ja) | 2009-04-27 | 2015-04-01 | 協和発酵キリン株式会社 | 血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体 |
| AU2010308030B2 (en) | 2009-10-12 | 2014-05-29 | Pfizer Inc. | Cancer treatment |
| ES2776980T3 (es) | 2009-12-23 | 2020-08-03 | Merck Sharp & Dohme | Línea celular 3M |
| EP2593594B1 (en) | 2010-07-16 | 2017-09-27 | Adimab, LLC | Antibody libraries |
| US8491901B2 (en) | 2010-11-19 | 2013-07-23 | Toshio Imai | Neutralizing anti-CCL20 antibodies |
| CN102559720B (zh) * | 2010-12-16 | 2015-05-13 | 中国科学院福建物质结构研究所 | 人源凝血因子xi催化结构域的表达、纯化及结晶 |
| KR102320178B1 (ko) | 2011-01-06 | 2021-11-02 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 |
| ES2785081T3 (es) | 2011-04-01 | 2020-10-05 | Memorial Sloan Kettering Cancer Center | Anticuerpos biespecíficos similares a receptores de células T específicos para un péptido de WT1 presentado por HLA-A2 |
| PL3424953T3 (pl) | 2011-06-06 | 2021-01-25 | Novo Nordisk A/S | Lecznicze przeciwciała |
| IL291613B1 (en) * | 2011-07-22 | 2025-08-01 | Csl Behring Gmbh | Inhibitory anti-factor xii/fxiia monoclonal antibodies, method of producing the same, pharmaceutical composition containing the same and medical uses |
| US8765385B2 (en) | 2011-10-27 | 2014-07-01 | Ravindra Kumar | Method of detection of neutralizing anti-actriib antibodies |
| EP2623110A1 (en) | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
| EP2650310B1 (en) | 2012-04-13 | 2016-06-08 | Rottapharm Biotech S.r.l. | Anti-ADAMTS-5 antibody, derivatives and uses thereof |
| HRP20181680T1 (hr) | 2012-05-10 | 2018-12-14 | Bayer Pharma Aktiengesellschaft | Protutijela koja su sposobna vezati se na koagulacijski faktor xi i/ili njegov aktivirani oblik faktora xia i njegova upotreba |
| WO2013173255A2 (en) | 2012-05-17 | 2013-11-21 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind egfr |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| MX2016011885A (es) | 2014-03-20 | 2016-12-02 | Japan As Represented By Director-General Of Nat Inst Of Infectious Diseases | Anticuerpo con actividad inhibidora de inyeccion frente al virus de hepatitis c. |
| CN106456763B (zh) | 2014-06-03 | 2018-03-13 | 埃克斯生物科技公司 | 用于治疗和预防金黄色葡萄球菌感染的组合物和方法 |
| SG11201700901SA (en) | 2014-08-08 | 2017-03-30 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| WO2016164637A1 (en) | 2015-04-07 | 2016-10-13 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
| HK1252675A1 (zh) | 2015-06-12 | 2019-05-31 | Alector Llc | 抗cd33抗体及其使用方法 |
| JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| US11066481B2 (en) | 2015-07-23 | 2021-07-20 | The Regents Of The University Of California | Antibodies to coagulation factor XIa and uses thereof |
| WO2017058944A1 (en) | 2015-09-29 | 2017-04-06 | Amgen Inc. | Asgr inhibitors |
-
2017
- 2017-01-19 WO PCT/US2017/014007 patent/WO2017127468A1/en not_active Ceased
- 2017-01-19 CN CN201780007555.0A patent/CN108884169B/zh not_active Expired - Fee Related
- 2017-01-19 JP JP2018537750A patent/JP7252760B2/ja active Active
- 2017-01-19 CN CN202210232062.XA patent/CN114539414B/zh active Active
- 2017-01-19 TW TW106101965A patent/TWI736575B/zh not_active IP Right Cessation
- 2017-01-19 RU RU2018129874A patent/RU2757314C2/ru active
- 2017-01-19 AR ARP170100143A patent/AR107505A1/es not_active Application Discontinuation
- 2017-01-19 EP EP17703278.6A patent/EP3405498A1/en active Pending
- 2017-01-19 JO JOP/2017/0013A patent/JOP20170013B1/ar active
- 2017-01-19 RU RU2021129189A patent/RU2021129189A/ru unknown
- 2017-01-19 BR BR112018014810-5A patent/BR112018014810A2/pt not_active IP Right Cessation
- 2017-01-19 AU AU2017209083A patent/AU2017209083A1/en not_active Abandoned
- 2017-01-19 CA CA3010224A patent/CA3010224A1/en active Pending
- 2017-01-19 MX MX2018008939A patent/MX378572B/es unknown
- 2017-01-19 MA MA043660A patent/MA43660A/fr unknown
- 2017-01-19 KR KR1020187023721A patent/KR20180104036A/ko not_active Withdrawn
- 2017-01-19 US US15/409,607 patent/US10053515B2/en active Active
-
2018
- 2018-07-20 MX MX2021000027A patent/MX2021000027A/es unknown
- 2018-08-13 US US16/101,861 patent/US10584179B2/en active Active
-
2021
- 2021-12-24 JP JP2021211379A patent/JP7366988B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180104036A (ko) | 2018-09-19 |
| CN108884169A (zh) | 2018-11-23 |
| CA3010224A1 (en) | 2017-07-27 |
| US20180362661A1 (en) | 2018-12-20 |
| JOP20170013B1 (ar) | 2021-08-17 |
| MX2021000027A (es) | 2021-03-09 |
| JP7366988B2 (ja) | 2023-10-23 |
| RU2018129874A (ru) | 2020-02-25 |
| RU2021129189A (ru) | 2021-11-15 |
| TW201728602A (zh) | 2017-08-16 |
| JP2019505527A (ja) | 2019-02-28 |
| JP2022046656A (ja) | 2022-03-23 |
| TWI736575B (zh) | 2021-08-21 |
| CN114539414A (zh) | 2022-05-27 |
| AU2017209083A1 (en) | 2018-07-12 |
| US20170226225A1 (en) | 2017-08-10 |
| JP7252760B2 (ja) | 2023-04-05 |
| US10584179B2 (en) | 2020-03-10 |
| MX2018008939A (es) | 2019-08-21 |
| US10053515B2 (en) | 2018-08-21 |
| CN108884169B (zh) | 2022-03-22 |
| AR107505A1 (es) | 2018-05-09 |
| CN114539414B (zh) | 2024-03-29 |
| MX378572B (es) | 2025-03-11 |
| BR112018014810A2 (pt) | 2018-12-11 |
| MA43660A (fr) | 2018-11-28 |
| WO2017127468A1 (en) | 2017-07-27 |
| EP3405498A1 (en) | 2018-11-28 |
| RU2757314C2 (ru) | 2021-10-13 |